Should You Add Illumina Stock to Your Portfolio Now?
Yahoo Finance
Read Full Article at Yahoo Finance →Ad Slot — In-Article (728x90)
ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
This is a summary. For the full story, read the original article at Yahoo Finance.
Original source: Yahoo Finance